Additionally, the 36-month beta value for INO is 1.72. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for INO is 35.85M and currently, short sellers hold a 15.41% ratio of that float. The average trading volume of INO on March 19, 2025 was 857.13K shares.
INO) stock’s latest price update
The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) has dropped by -6.70 compared to previous close of 2.10. Despite this, the company has seen a fall of -4.42% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-18 that Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennie Willson – IR Jacqui Shea – President & CEO Mike Sumner – Chief Medical Officer Steve Egge – Chief Commercial Officer Peter Kies – CFO Conference Call Participants Roy Buchanan – Citizens JMP Jay Olson – Oppenheimer Sudan Loganathan – Stephens Yi Chen – H.C. Wainwright Anish Nikhanj – RBC Liang Cheng – Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2024 Financial Results Conference Call.
INO’s Market Performance
INO’s stock has fallen by -4.42% in the past week, with a monthly drop of -10.53% and a quarterly drop of -15.55%. The volatility ratio for the week is 6.76% while the volatility levels for the last 30 days are 7.15% for Inovio Pharmaceuticals Inc The simple moving average for the past 20 days is -2.30% for INO’s stock, with a -64.30% simple moving average for the past 200 days.
Analysts’ Opinion of INO
Many brokerage firms have already submitted their reports for INO stocks, with Stephens repeating the rating for INO by listing it as a “Overweight.” The predicted price for INO in the upcoming period, according to Stephens is $20 based on the research report published on May 14, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see INO reach a price target of $4. The rating they have provided for INO stocks is “Outperform” according to the report published on January 25th, 2024.
INO Trading at -4.15% from the 50-Day Moving Average
After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.71% of loss for the given period.
Volatility was left at 7.15%, however, over the last 30 days, the volatility rate increased by 6.76%, as shares sank -9.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.04% upper at present.
During the last 5 trading sessions, INO fell by -2.44%, which changed the moving average for the period of 200-days by -79.53% in comparison to the 20-day moving average, which settled at $2.01. In addition, Inovio Pharmaceuticals Inc saw 7.07% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for INO
Current profitability levels for the company are sitting at:
- -587.1 for the present operating margin
- -7.67 for the gross margin
The net margin for Inovio Pharmaceuticals Inc stands at -124147.37. The total capital return value is set at -1.43. Equity return is now at value -106.64, with -75.21 for asset returns.
Based on Inovio Pharmaceuticals Inc (INO), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -6784.78. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -259.53.
Currently, EBITDA for the company is -112.4 billion with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of 296.2. The receivables turnover for the company is 0.11for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.88.
Conclusion
In conclusion, Inovio Pharmaceuticals Inc (INO) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
